SCHEMBL5375962

SCHEMBL5375962

OCC(CO)(CO)COCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.67
POLB P06746 1/20 0.67
TSHR P16473 3/20 0.56
CA1 P00915 5/20 0.46
CA2 P00918 3/20 0.43
CA9 Q16790 3/20 0.43
CA7 P43166 2/20 0.43
IDO1 P14902 1/20 0.41
ALDH1A1 P00352 4/20 0.41
AGXT P21549 1/20 0.40
SLC6A2 P23975 2/20 0.39
SLC6A3 Q01959 2/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
PTGS1 P23219 1/20 0.39
CYP2C19 P33261 1/20 0.39
PTGS2 P35354 1/20 0.39
HIF1A Q16665 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29705157 0.96 KDM4E (0.62) KDM4EPOLBTSHRCA1CA2
SCHEMBL3549969 0.96 KDM4E (0.67) KDM4EPOLBTSHRCA1CA2
SCHEMBL8307260 0.96 KDM4E (0.67) KDM4EPOLBTSHRCA1CA2
SCHEMBL13950710 0.90 KDM4E (0.56) KDM4EPOLBTSHRCA1CA2
SCHEMBL8352022 0.89 KDM4E (0.59) KDM4EPOLBTSHRCA1CA2
SCHEMBL22483593 0.89 KDM4E (0.59) KDM4EPOLBTSHRCA1CA2
SCHEMBL10704165 0.89 KDM4E (0.59) KDM4EPOLBTSHRCA1CA2
SCHEMBL19437584 0.87 KDM4E (0.53) KDM4EPOLBTSHRCA1SLC6A2
SCHEMBL18929793 0.87 KDM4E (0.57) KDM4EPOLBTSHRCA1CA2
SCHEMBL13950713 0.87 KDM4E (0.53) KDM4EPOLBTSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4282857-B1 RADIOACTIVE HALOGEN-LABELED PRECURSOR COMPOUND INST OF SCIENCE TOKYO (JP) 2026-04-15 EP disclosed
US-20240173305-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 US disclosed
EP-3813946-B1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-05-22 EP disclosed
CN-117843659-A Rapamycin analogues and uses thereof 詹森药业有限公司 2024-04-09 CN disclosed
US-11944605-B2 Rapamycin analogs and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-02 US disclosed
US-20240034721-A1 RADIOACTIVE HALOGEN LABELING PRECURSOR COMPOUND TOKYO INSTITUTE OF TECHNOLOGY (JP) 2024-02-01 US disclosed
EP-4302827-A2 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN Pharmaceutica NV (BE) 2024-01-10 EP disclosed
EP-4282857-A1 RADIOACTIVE HALOGEN-LABELED PRECURSOR COMPOUND Tokyo Institute of Technology (JP) 2023-11-29 EP disclosed
CN-112423843-B Rapamycin analogues and uses thereof 詹森药业有限公司 2023-11-28 CN disclosed
US-20230357776-A1 COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION IONIS PHARMACEUTICALS, INC. (US) 2023-11-09 US disclosed
US-8252778-B2 Highly fluorinated oils and surfactants and methods of making and using same UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-08-28 US disclosed
US-20090264397-A1 HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-10-22 US disclosed
US-7226578-B2 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SHERING AG (DE) 2007-06-05 US disclosed
CN-1910230-A Fire-retardancy styrene resin composition and its forming product TEIJIN CHEMICALS LTD (JP) 2007-02-07 CN disclosed
US-6916461-B2 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SCHERING AG (DE) 2005-07-12 US disclosed
US-20050147563-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-07-07 US disclosed
US-20030232012-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis SCHERING AG (DE) 2003-12-18 US disclosed
US-6468502-B1 PARAMAGNETIC MACROMOLECULES WITH HIGHER PROTON RELAXIVITY; LOWER DOSAGE AND INCREASED SIGNAL INTENSITY; DETECTING VASCULAR DISEASES; DIFFERENTIATING TISSUE BLOOD SUPPLY LEVELS; DISTINGUISHING MYOCARDIAL INFARCTION FROM ISCHEMIA SCHERING AKTIENGESELLSCHAFT (DE) 2002-10-22 US disclosed
US-6180113-B1 USED IN TUMOR THERAPY AND INTERVENTIONAL RADIOLOGY SCHERING AG (DE) 2001-01-30 US disclosed
US-4451509-A WATERPROOF COATING FOR WOOD BAYER AKTIENGESELLSCHAFT (DE) 1984-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034721-A1 RADIOACTIVE HALOGEN LABELING PRECURSOR COMPOUND GPR119, SLC5A2, GCKR KDM4E 3327/4885POLB 2274/4885TSHR 22/4885
US-20050147563-A1 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis FABP1, FLOT1, AFF1 KDM4E 4553/4885POLB 1811/4885TSHR 892/4885
US-20090264397-A1 HIGHLY FLUORINATED OILS AND SURFACTANTS AND METHODS OF MAKING AND USING SAME FLOT1, ABCB4, SGMS1 KDM4E 4290/4885POLB 2810/4885TSHR 3279/4885
US-11944605-B2 Rapamycin analogs and uses thereof RICTOR, MTOR, RPTOR KDM4E 1565/4885POLB 3464/4885TSHR 3810/4885
US-20240173305-A1 RAPAMYCIN ANALOGS AND USES THEREOF RICTOR, MTOR, RPTOR KDM4E 1565/4885POLB 3464/4885TSHR 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.